Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Publication|Articles|March 4, 2025
- April 2025
- Volume 31
- Issue Spec. No. 4
- Pages: SP230
Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology
Author(s)Mary Caffrey
Advertisement
Advertisement
In January 2025, former FDA Commissioner Stephen Hahn, MD, and fellow panelists at the JP Morgan investors conference observed that pharma no longer follows a path of establishing a presence in one tumor type before moving to the next—today’s news is all about targets, regardless of where cancer emerges.1
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement